Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_2
3
38%
Ph phase_1
2
25%
Ph phase_3
2
25%

Phase Distribution

2

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(4)

Detailed Status

Completed4
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
57.1%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 23 (42.9%)
Phase 32 (28.6%)

Trials by Status

completed450%
withdrawn113%
terminated338%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NCT00788957
completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02154490
terminatedphase_2

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

NCT02926638
completedphase_2

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01039207
terminatedphase_3

A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer

NCT02137343
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00788957Phase 1

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Completed
NCT02154490

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed
NCT02926638Phase 2

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Terminated
NCT01039207Phase 2

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed
NCT02137343Phase 3

A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer

Terminated
NCT01791374Phase 1

Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

Completed
NCT01697072Phase 3

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Terminated
NCT01105390Phase 2

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8